We use cookies for a better user experience. Read our Privacy Policy

I Agree

Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market (Treatment: Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Benign Prostatic Hyperplasia Treatment Market Outlook 2031

  • The global benign prostatic hyperplasia treatment market was valued at US$ 6.9 Bn in 2021
  • The global market is projected to grow at a CAGR of 5.5% from 2022 to 2031
  • The global benign prostatic hyperplasia treatment market is anticipated to reach more than US$ 11.9 Bn by the end of 2031

Analysts’ Viewpoint on Benign Prostatic Hyperplasia Treatment Market Scenario

Benign prostatic hyperplasia (BPH) is a noncancerous growth of cells within the prostate gland. It first affects the inside part of the prostate. Enlargement of the prostate then gradually causes squeezing of the urethra. BPH medical treatment options available in the market are BPH medications, surgery, and minimally invasive surgeries. Rise in prevalence of benign prostatic hyperplasia due to the aging male population, obesity, and physical inactivity; and increase in awareness about the availability of benign prostatic hyperplasia drugs are expected to create lucrative opportunities for the global benign prostatic hyperplasia prostate treatment market during the forecast period.

Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market Introduction

The prostate is a walnut-sized gland situated just below the bladder in front of the rectum and adjacent to the urethra as part of the male reproductive system. The prostate gland, which consists of four lobes (anterior, posterior, lateral, and medial), generates a fluid that combines with seminal vesicle secretions to generate most of the seminal fluid volume.

Benign prostatic hyperplasia (BPH) is a progressive disorder, wherein the prostate expands as part of the aging process or as a result of a disease. Incidence of benign prostatic hyperplasia increases significantly with age. Prostate development between puberty and the middle age is generally negligible. The exact cause of BPH is unknown, but the disease most frequently occurs in elderly males. It is probably caused due to hormonal changes. Several theories suggest that greater estrogen or dihydrotestosterone concentrations lead to hyperplastic development, although none are conclusive. The function of testosterone in BPH growth is still uncertain.

Currently, benign prostatic hyperplasia is one of the most common benign tumors observed in men across the globe. Benign prostatic hyperplasia is more prevalent in men aged 40 years and above. A study by the National Center for Biotechnology Information (NCBI) stated that the risk of benign prostatic hyperplasia is less common among the population of Asia than in the Caucasian population in the West. Around 50% of men below the age of 60 who underwent surgery for benign prostatic hyperplasia had a heritable form of the disease.

With progressively aging population and changing population profile in nearly all societies, benign prostatic hyperplasia is expected to become a major challenge for all health care systems. It is anticipated to become even more prevalent in men during the forecast period.

Request a sample to get extensive insights into the Benign Prostatic Hyperplasia Treatment Market

Increase in Geriatric Population to Drive Demand for Benign Prostatic Hyperplasia Treatment

As per the benign prostatic hyperplasia treatment market analysis, increase in geriatric population is a major driver of the global market. Elderly individuals increase the patient pool in major regions of the world. According to the World Health Organization (WHO), the global geriatric population is likely to reach 2 billion (22% of the global population) by 2050 as against 962 million in 2017. The global geriatric population is expected to increase at the fastest rate in developed countries such as the U.S., the U.K., and Japan. Brazil, China, Thailand, and South Korea are likely to have a large geriatric population in the shortest span of time in the near future.

Surge in geriatric population is projected to propel the global benign prostatic hyperplasia treatment market size, as the population is more prone to various age-related as well as chronic diseases. The need for benign prostatic hyperplasia treatment among such patients is relatively higher. This is anticipated to drive the global benign prostatic hyperplasia treatment market.

Rise in Adoption of Minimally Invasive Surgeries to Propel Benign Global Prostatic Hyperplasia Treatment Market

Established types of minimally invasive surgery include electrocautery-based TURP, transurethral incision of the prostate (TUIP), and transurethral vaporization of the prostate (TUVP), although the latter technique is used infrequently. TURP is the most popular minimally invasive surgical procedure for relieving severe medical BPH symptoms, while radical prostatectomy based on open surgery is rarely used in the therapy of BPH, almost solely for indications of prostate cancer.

Adoption of minimally invasive surgeries has been increasing significantly due to various advantages such as less post-operative pain, less blood loss, reduced hospital stay, and faster recovery. This is likely to propel the global benign prostatic hyperplasia (BPH) treatment market during the forecast period.

Request a custom report on Benign Prostatic Hyperplasia Treatment Market

Growth in Geriatric Population to Augment Global Benign Prostatic Hyperplasia Treatment Market

Prostate development is generally negligible between puberty and middle age; however, hormonal modifications could cause the gland to enlarge when a person reaches age 40 (for most males). Studies of autopsy have found the histological incidence of BPH. Thus, increase in geriatric population that is prone to urological diseases is projected to drive the benign prostatic hyperplasia (BPH) treatment market in the U.S.

Proven High Efficacy to Drive Alpha-blockers Segment

Alpha-blockers block0020alpha-adrenoceptors on the smooth muscle of the prostate, prostatic urethra, and bladder neck, leading to decreased muscle tone and reduction in the bladder obstruction. Alpha-blockers include alfuzosin hydrochloride (Uroxatral), silodosin (Rapaflo), tamsulosin hydrochloride (Flomax), and terazosin (Hytrin). Alpha-blockers are prescribed for men who have moderate to severe BPH symptoms. The proven high efficacy of alpha-blockers is expected to propel the alpha-blockers segment during the forecast period.

Most Preferred Approach for Benign Prostatic Hyperplasia Treatment Propelling TURP Segment

Currently, transurethral resection of the prostate (TURP) is the most preferred approach used by surgeons or urologists for benign prostatic hyperplasia treatment. TURP is an endoscopic electrosurgical procedure involving the removal of a portion of the prostate to relieve voiding obstruction associated with BPH. A specialized cystoscope known as a resectoscope is inserted into the urethra and threaded into the bladder. Following the procedure, most patients stay in the hospital between one and four days for observation. However, the trend is to perform TURP on an outpatient basis, and select patients are discharged within 24 hours of admission.

Regional Outlook of Benign Prostatic Hyperplasia Treatment Market

North America was the leading market for benign prostatic hyperplasia treatment in 2021. Aging population, increase in incidence of benign prostatic hyperplasia, and highly structured health care industry are augmenting the market in the region. Current disease trends indicate that the number of men with benign prostatic hyperplasia and lower urinary tract conditions will increase at a rapid pace in the U.S. in the near future. Rapidly aging population of the U.S. coupled with rise in diabetes and obesity is likely to drive the prevalence of benign prostatic hyperplasia and lower urinary tract conditions. Thus, demand for prostate hypertrophy treatment is estimated to increase in the U.S. in the near future.

Analysis of Key Players Global Benign Prostatic Hyperplasia Treatment Market

The report also provides profiles of leading players operating in the global benign prostatic hyperplasia treatment market. These include Abbott, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Sanofi, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser Surgeries, and Olympus Corporation.

Key Developments in Global Benign Prostatic Hyperplasia Treatment Market

  • In April 2022, Teleflex announced the launch of the UroLift System in Japan for the treatment of benign prostatic hyperplasia (BPH). The FDA had cleared the usage of UroLift System for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
  • In September 2018, Boston Scientific Corporation acquired Augmenix, the developer of SpaceOAR intended to reduce common and debilitating side effects for men who undergo prostate cancer radiotherapy
  • In March 2018, Boston Scientific Corporation acquired NxThera, the developer of the Rezūm system, which is a minimally invasive therapy for patients with BPH
  • In September 2017, Teleflex Incorporated and NeoTract, Inc. entered into a definitive agreement for the acquisition of NeoTract in a transaction valued up to US$ 1.1 Bn. NeoTract is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia.

Each of these players has been profiled in the benign prostatic hyperplasia treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Benign Prostatic Hyperplasia Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 6.9 Bn

Market Forecast Value in 2031

More than US$ 11.9 Bn

Growth Rate

CAGR of 5.5% from 2022–2031

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview.

Competition Landscape

  • Market share analysis by the company (2021)
  • Company profiles section includes an overview, product portfolio, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment
    • Drug Class
      • Alpha-blockers
      • 5-Alpha-reductase Inhibitor (5-ARIs)
      • Phosphodiesterase-5 Enzyme Inhibitor
      • Others
    • Minimally Invasive Surgeries
      • Transurethral Resection of the Prostate (TURP)
      • Transurethral Incision of the Prostate (TUIP)
      • Robotic Surgeries
      • Transurethral Microwave Thermotherapy (TUMT)
      • Prostatic Urethral Lift
      • Others
    • Laser Therapy
    • Others
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • U.K.
  • France
  • Italy
  • Germany
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Endo International plc
  • Urologix, LLC
  • LISA Laser
  • Olympus Corporation

Customization Scope

Available upon request

Pricing

Available upon request

Benign Prostatic Hyperplasia Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global benign prostatic hyperplasia treatment market in 2021?

The global benign prostatic hyperplasia treatment market was valued at US$ 6.9 Bn in 2021

How big will be the global benign prostatic hyperplasia treatment market by 2031?

The global market is projected to reach more than US$ 11.9 Bn by 2031

What was the CAGR of the global benign prostatic hyperplasia treatment market from 2017 to 2021?

The global benign prostatic hyperplasia treatment market grew at a CAGR of 0.2% from 2017 to 2021

What will be the CAGR of the global benign prostatic hyperplasia treatment market during the forecast period (2022–2031)?

The global benign prostatic hyperplasia treatment market is anticipated to grow at a CAGR of 5.5% from 2022 to 2031

What was the market share of the leading segment of the global market?

The drug class segment held around 45% share of the global benign prostatic hyperplasia treatment market in 2021

Who are the prominent players in the global market?

Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, and Olympus Corporation

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Benign Prostatic Hyperplasia Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Prevalence of Benign Prostatic Hyperplasia by region/globally

    5.3. Re-imbursement Scenario

    5.4. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, By Treatment

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment, 2017–2031

        6.3.1. Drug Class

            6.3.1.1. Alpha-Blockers

            6.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            6.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            6.3.1.4. Others

        6.3.2. Minimally Invasive Surgeries

            6.3.2.1. Transurethral Resection of the Prostate (TURP)

            6.3.2.2. Transurethral Incision of the Prostate (TUIP)

            6.3.2.3. Robotic Surgeries

            6.3.2.4. Transurethral Microwave Thermotherapy (TUMT)

            6.3.2.5. Prostatic Urethral Lift

        6.3.3. Laser Therapy

        6.3.4. Others

    6.4. Market Attractiveness Analysis, by Treatment

7. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2031

        7.3.1. Hospitals

        7.3.2. Ambulatory Surgical Centers

        7.3.3. Specialty Clinics

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by End-user

8. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Treatment, 2017–2031

        9.2.1. Drug Class

            9.2.1.1. Alpha-Blockers

            9.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            9.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            9.2.1.4. Others

        9.2.2. Minimally Invasive Surgeries

            9.2.2.1. Transurethral Resection of the Prostate (TURP)

            9.2.2.2. Transurethral Incision of the Prostate (TUIP)

            9.2.2.3. Robotic Surgeries

            9.2.2.4. Transurethral Microwave Thermotherapy (TUMT

            9.2.2.5. Prostatic Urethral Lift

        9.2.3. Laser Therapy

        9.2.4. Others

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Hospitals

        9.3.2. Ambulatory Surgical Centers

        9.3.3. Specialty Clinics

        9.3.4. Others

    9.4. Market Value Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Treatment

        9.5.2. By End-user

        9.5.3. By Country

10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment, 2017–2031

        10.2.1. Drug Class

            10.2.1.1. Alpha-Blockers

            10.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            10.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            10.2.1.4. Others

        10.2.2. Minimally Invasive Surgeries

            10.2.2.1. Transurethral Resection of the Prostate (TURP)

            10.2.2.2. Transurethral Incision of the Prostate (TUIP)

            10.2.2.3. Robotic Surgeries

            10.2.2.4. Transurethral Microwave Thermotherapy (TUMT)

            10.2.2.5. Prostatic Urethral Lift

        10.2.3. Laser Therapy

        10.2.4. Others

    10.3. Market Value Forecast, by End-user, 2017–2031

        10.3.1. Hospitals

        10.3.2. Ambulatory Surgical Centers

        10.3.3. Specialty Clinics

        10.3.4. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Treatment

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment, 2017–2031

        11.2.1. Drug Class

            11.2.1.1. Alpha-Blockers

            11.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            11.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            11.2.1.4. Others

        11.2.2. Minimally Invasive Surgeries

            11.2.2.1. Transurethral Resection of the Prostate (TURP)

            11.2.2.2. Transurethral Incision of the Prostate (TUIP)

            11.2.2.3. Robotic Surgeries

            11.2.2.4. Transurethral Microwave Thermotherapy (TUMT)

            11.2.2.5. Prostatic Urethral Lift

        11.2.3. Laser Therapy

        11.2.4. Others

    11.3. Market Value Forecast, by End-user, 2017–2031

        11.3.1. Hospitals

        11.3.2. Ambulatory Surgical Centers

        11.3.3. Specialty Clinics

        11.3.4. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Treatment

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment, 2017–2031

        12.2.1. Drug Class

            12.2.1.1. Alpha-Blockers

            12.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            12.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            12.2.1.4. Others

        12.2.2. Minimally Invasive Surgeries

            12.2.2.1. Transurethral Resection of the Prostate (TURP)

            12.2.2.2. Transurethral Incision of the Prostate (TUIP)

            12.2.2.3. Robotic Surgeries

            12.2.2.4. Transurethral Microwave Thermotherapy (TUMT)

            12.2.2.5. Prostatic Urethral Lift

        12.2.3. Laser Therapy

        12.2.4. Others

    12.3. Market Value Forecast, by End-user, 2017–2031

        12.3.1. Hospitals

        12.3.2. Ambulatory Surgical Centers

        12.3.3. Specialty Clinics

        12.3.4. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Treatment

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment, 2017–2031

        13.2.1. Drug Class

            13.2.1.1. Alpha-Blockers

            13.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            13.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            13.2.1.4. Others

        13.2.2. Minimally Invasive Surgeries

            13.2.2.1. Transurethral Resection of the Prostate (TURP)

            13.2.2.2. Transurethral Incision of the Prostate (TUIP)

            13.2.2.3. Robotic Surgeries

            13.2.2.4. Transurethral Microwave Thermotherapy (TUMT)

            13.2.2.5. Prostatic Urethral Lift

        13.2.3. Laser Therapy

        13.2.4. Others

    13.3. Market Value Forecast, by End-user, 2017–2031

        13.3.1. Hospitals

        13.3.2. Ambulatory Surgical Centers

        13.3.3. Specialty Clinics

        13.3.4. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Treatment

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2021

    14.3. Company Profiles

        14.3.1. Boston Scientific Corporation

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. Financial Overview

            14.3.1.4. SWOT Analysis

            14.3.1.5. Strategic Overview

        14.3.2. Teleflex Incorporated

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. Financial Overview

            14.3.2.4. SWOT Analysis

            14.3.2.5. Strategic Overview

        14.3.3. Endo International plc

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. Financial Overview

            14.3.3.4. SWOT Analysis

            14.3.3.5. Strategic Overview

        14.3.4. Urologix, LLC

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. Financial Overview

            14.3.4.4. SWOT Analysis

           14.3.3.5. Strategic Overview

        14.3.5. LISA Laser

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. Financial Overview

            14.3.5.4. SWOT Analysis

            14.3.5.5. Strategic Overview

        14.3.6. Olympus Corporation

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. Financial Overview

            14.3.6.4. SWOT Analysis

            14.3.6.5. Strategic Overview

List of Tables

Table 01: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031

Table 02: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031

Table 03: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031

Table 04: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 05: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031

Table 08: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031

Table 09: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031

Table 10: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 11: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 12: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 13: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031

Table 14: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031

Table 15: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031

Table 16: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 17: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 18: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 19: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031

Table 20: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031

Table 21: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2031

Table 22: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 23: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 24: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 25: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031

Table 26: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031

Table 27: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031

Table 28: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 29: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 30: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 31: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017–2031

Table 32: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017–2031

Table 33: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017–2031

Table 34: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017‒2031

Table 35: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

List of Figures

Figure 01: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Treatment, 2021

Figure 03: Global Benign Prostatic Hyperplasia Treatment Market Value Share, by End-user, 2021

Figure 04: Global Benign Prostatic Hyperplasia Treatment Market, by Treatment, 2021 and 2031

Figure 05: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 06: Global Benign Prostatic Hyperplasia Treatment Market, by Drug Class, 2021–2031

Figure 07: Global Benign Prostatic Hyperplasia Treatment Market, by Minimally Invasive Surgeries, 2021–2031

Figure 08: Global Benign Prostatic Hyperplasia Treatment Market, by Laser Therapy, 2021–2031

Figure 09: Global Benign Prostatic Hyperplasia Treatment Market, by Others, 2021–2031

Figure 10: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031

Figure 11: Global Benign Prostatic Hyperplasia Treatment Market, by End-user, 2021 and 2031

Figure 12: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 13: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Hospitals, 2017–2031

Figure 14: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Ambulatory Surgical Centers, 2017–2031

Figure 15: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Specialty Clinics, 2017–2031

Figure 16: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Others, 2017–2031

Figure 17: Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Region, 2021 and 2031

Figure 18: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region, 2017–2031

Figure 19: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 20: North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 21: North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 22: North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 23: North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 24: North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031

Figure 25: North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 26: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 27: Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 28: Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 29: Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 30: Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 31: Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031

Figure 32: Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 33: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 34: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 35: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 36: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 37: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 38: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031

Figure 39: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 40: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 41: Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 42: Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 43: Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 44: Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 45: Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031

Figure 46: Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Figure 47: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 48: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 49: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 50: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 51: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021–2031

Figure 52: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031

Figure 53: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

116

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved